The pharmacology of a new nitric oxide donor: B-NOD.
We describe here a new compound, B-NOD, which, in vitro and in situ, releases nitric oxide (NO). Its activity in situ persists for more than 7 h, it does not cause a fall in blood pressure or an increase in heart rate and can be orally administered. It increases cyclic guanosine monophosphate (cGMP) and prevents platelet aggregation. In vitro, its release of NO is augmented by the presence of living cells (blood platelets). B-NOD may be useful in a number of clinical conditions in which prolonged release of NO without hemodynamic effects are desirable. A combination of aspirin with B-NOD could be formulated in which the individual concentrations of aspirin and B-NOD may be useful in the long-term treatment of coronary artery disease and in clinical situations in which long-term release of NO may be beneficial.
Bing
R J
RJ
Department of Experimental Cardiology, Huntington Medical Research Institutes, 99 North El Molino Avenue, Pasadena, California 91101, USA. cardio@hmri.org
Yamamoto
T
T
Kim
H
H
Grubbs
R H
RH
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D006152:Cyclic GMP / Q000378:metabolism; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009566:Nitrates / Q000494:pharmacology*; D009569:Nitric Oxide / Q000096:biosynthesis; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011817:Rabbits; D012459:Salicylates / Q000494:pharmacology*
C413747:2-hydroxybenzoic acid 3-nitrooxymethylphenyl ester; D009566:Nitrates; D020030:Nitric Oxide Donors; D010975:Platelet Aggregation Inhibitors; D012459:Salicylates; D009569:Nitric Oxide; D006152:Cyclic GMP